Drugs

, Volume 52, Issue 2, pp 209–224 | Cite as

Treatment and Prophylaxis of Tinea Infections

  • Géerald E. Piérard
  • Jorge E. Arrese
  • Claudine Piérard-Franchimont
Disease Management

Summary

Superficial fungal infections affect millions of people throughout the world. Among them, tinea represents cutaneous infections by dermatophytes. Therapeutic strategies depend upon the affected body site. Hence, clinicians distinguish several types of tinea including the corporis, faciei, cruris, pedis, manuum, capitis, barbae and unguium variants. There are several ways of tackling the tinea problem. Numerous topical and oral antifungals are available today. Topical antifungals remain the most commonly recommended treatment for many superficial dermatophytoses. Active compounds include imidazoles, morpholines and allylamines, with a few other miscellaneous drugs. The recent development of new generation oral agents (fluconazole, itraconazole, terbinafine) has enhanced the armamentarium against difficult-to-treat tineas. The antifungal efficacy and pharmacokinetic profiles of these drugs allow shorter durations of treatment and the innovative use of intermittent pulse regimens. The modern formulations fully meet the requirements of being well tolerated, involving little risk and acting specifically against relevant pathogens. However, the response rates to date do not always come up to the high expectations offered by in vitro studies.

Keywords

Itraconazole Terbinafine Griseofulvin Dermatophytosis Tinea Capitis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Odds FC, Arai T, Disalvo AF, et al. Nomenclature of fungal diseases: a report and recommendations from a sub-committee of the International Society for Human and Animal Mycology. J Med Vet Mycol 1992; 30: 11–25CrossRefGoogle Scholar
  2. 2.
    Elewski BE, Hazen PG. The superficial mycoses and the dermatophytes. J Am Acad Dermatol 1989; 21: 655–73PubMedCrossRefGoogle Scholar
  3. 3.
    Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 1994; 31: S21–5PubMedCrossRefGoogle Scholar
  4. 4.
    Degreef HJ, De Doncker PRG. Current therapy of dermatophytosis. J Am Acad Dermatol 1994; 31: S25–30PubMedCrossRefGoogle Scholar
  5. 5.
    Georgii A, Korting HC. Antifungal susceptibility testing with dermatophytes. Mycoses 1991; 34: 193–9PubMedCrossRefGoogle Scholar
  6. 6.
    Dahl MV. Dermatophytosis and the immune response. J Am Acad Dermatol 1994; 31: S34–41PubMedCrossRefGoogle Scholar
  7. 7.
    Gip L. The in vitro determination of lingering antimycotic effect of two 1% omoconazole-nitrate cream formulations following single topical application. Mycoses 1988; 31: 155–8PubMedCrossRefGoogle Scholar
  8. 8.
    Rurangirwa A, Piérard-Franchimont C, Piérard GE. Culture of fungi on cyanoacrylate skin surface strippings: a quantitative bioassay for evaluating antifungal drugs. Clin Exp Dermatol 1989; 14: 425–8PubMedCrossRefGoogle Scholar
  9. 9.
    Rurangirwa A, Van Puyvelde L, Piérard GE. Culture de champignons sur couche cornée: évaluation de l’action antifongique de plantes médicinales rwandaises. Afr J Dermatol 1990; 3: 11–6Google Scholar
  10. 10.
    Aljabre SHM, Scott EM, Shankland GS. In vitro susceptibility of Trichophyton mentagrophytes arthroconidia to clotrimazole and griseofulvin in human corneocyte suspensions. Mycoses 1991; 34: 479–82PubMedCrossRefGoogle Scholar
  11. 11.
    Piérard GE, Rurangirwa A, Piérard-Franchimont C. Bioavailability of fluconazole and ketoconazole in human stratum corneum and oral mucosa. Clin Exp Dermatol 1991; 16: 168–71PubMedCrossRefGoogle Scholar
  12. 12.
    Piérard GE, Piérard-Franchimont C, Arrese Estrada J. Comparative study of the activity and lingering effect of topical anti-fungals. Skin Pharmacol 1993; 6: 208–14PubMedCrossRefGoogle Scholar
  13. 13.
    Arrese JE, Schrooten P, De Doncker P, et al. Fungal cultures on cyanoacrylate skin surface strippings as a dose-finding method for topical antifungals: a placebo-controlled study with itraconazole 0.25% and 0.50% cream. J Med Vet Mycol 1995; 33: 127–30PubMedCrossRefGoogle Scholar
  14. 14.
    Piérard GE, Arrese JE, De Doncker P. Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad Dermatol 1995; 32: 429–35PubMedCrossRefGoogle Scholar
  15. 15.
    Kerridge D. Mode of action of clinically important antifungal drugs. Adv Microb Physiol 1986; 27: 1–72PubMedCrossRefGoogle Scholar
  16. 16.
    Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part I. J Am Acad Dermatol 1994; 30: 677–98PubMedCrossRefGoogle Scholar
  17. 17.
    Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994; 30: 911–33PubMedCrossRefGoogle Scholar
  18. 18.
    Hay RJ. Antifungal drugs on the horizon. J Am Acad Dermatol 1994; 31: S82–6PubMedCrossRefGoogle Scholar
  19. 19.
    Gull K, Trinci APJ. Griseofulvin inhibits fungal mitosis. Nature 1973; 244: 292–4PubMedCrossRefGoogle Scholar
  20. 20.
    Lenhart K. Griseofulvin resistance in dermatophytes. Experientia 1970; 26: 109–10PubMedCrossRefGoogle Scholar
  21. 21.
    Artis WM, Odle BM, Jones HE. Griseofulvin-resistant dermatophytosis correlates with in vitro resistance. Arch Dermatol 1981; 117: 16–9PubMedCrossRefGoogle Scholar
  22. 22.
    Harris R, Jones HE, Artis WM. Orally administered ketoconazole: route of delivery to stratum corneum. Antimicrob Agents Chemother 1983; 24: 876–82PubMedCrossRefGoogle Scholar
  23. 23.
    Haria M, Bryson HM, Goa KL. Itraconazole: a reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996 Apr; 51(4): 585–620PubMedCrossRefGoogle Scholar
  24. 24.
    Wiedfeuer A, Seidl HP. The in vitro activity of fluconazole against fungi involved in dermal infections. Mycoses 1994; 37: 447–9CrossRefGoogle Scholar
  25. 25.
    Van Cutsem J. An investigation of the in vitro activity and antifungal spectrum of itraconazole and terbinafine in relation to in vivo efficacy in dermatophytosis. J Mycol Med 1994; 4: 137–44Google Scholar
  26. 26.
    Hiratani T, Asagi Y, Matsusaka A, et al. in vitro antifungal activity of amorolfine, a new morpholine antimycotic agent. Jap J Antibiot 1991; 1006: 44–9Google Scholar
  27. 27.
    Polak-Wyss A. Mechanism of action of antifungals and combination therapy. J Eur Acad Dermatol Venereol 1995; 4 Suppl. 1: 11–6CrossRefGoogle Scholar
  28. 28.
    Birnbaum JE. Pharmacology of the allylamines. J Am Acad Dermatol 1990; 23: 783–5CrossRefGoogle Scholar
  29. 29.
    Monk J, Brogden RN. Naftifine: a review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs 1991; 42: 659–72PubMedCrossRefGoogle Scholar
  30. 30.
    Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259–84PubMedCrossRefGoogle Scholar
  31. 31.
    Clayton YM. Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br J Dermatol 1994; 130 Suppl. 43: 7–8PubMedCrossRefGoogle Scholar
  32. 32.
    Ryder NS, Frank I. Interaction of terbinafine with human serum and serum proteins. J Med Vet Mycol 1992; 30: 451–60PubMedCrossRefGoogle Scholar
  33. 33.
    Barrett-Bee KJ, Lane AC, Turner RW. The mode of antifungal action of tolnaftate. J Med Vet Mycol 1986; 24: 155–60PubMedCrossRefGoogle Scholar
  34. 34.
    Gupta MP, Kapur N, Bala I, et al. Studies on the mode of action of tolnaftate in Microsporum gypseum. J Med Vet Mycol 1991; 29: 45–52PubMedCrossRefGoogle Scholar
  35. 35.
    Abrams BB, Hanel H, Hoehler T. Ciclopirox olamine: a hydroxypyridone antifungal agent. Clin Dermatol 1991; 9: 471–7PubMedCrossRefGoogle Scholar
  36. 36.
    Polak A. Combination of amorolfine with various antifungal drugs in dermatophytosis. Mycoses 1993; 36: 43–9PubMedCrossRefGoogle Scholar
  37. 37.
    Smith EB. Topical antifungal agents. Dermatol Clin 1984; 2: 109–13Google Scholar
  38. 38.
    Hernandez-Perez E. Bifonazole cream: once-a-day application every second day in tinea cruris and corporis. Dermatologica 1984; 169: 93–8PubMedGoogle Scholar
  39. 39.
    Lücker PW, Beubler E, Kukovetz WR, et al. Retention time and concentration in human skin of bifonazole and clotrimazole. Dermatologica 1984; 169 Suppl. 1: 51–6PubMedGoogle Scholar
  40. 40.
    Odds FC, Webster CE, Abbott AB. Antifungal relative inhibition factors: BAY 1-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole, and vibunazole (BAYn-7133) compared in vitro with nine established antifungal agents. J Antimicrob Chemother 1984; 14: 105–14PubMedCrossRefGoogle Scholar
  41. 41.
    Jung EG, Bisco A, Azzollini E, et al. Fenticonazole cream once daily in dermatomycosis, a double-blind controlled trial versus bifonazole. Dermatologica 1988; 177: 104–8PubMedCrossRefGoogle Scholar
  42. 42.
    Wheatley D, Richardson MD, Scott EM. Tinea infections treated with bifonazole gel. Mycoses 1988; 31: 471–5PubMedCrossRefGoogle Scholar
  43. 43.
    Lackner TE, Clissold SP. Bifonazole: a review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs 1989; 38: 204–25PubMedCrossRefGoogle Scholar
  44. 44.
    Alomar A, Videla S, Delgadillo J, et al. Flutrimazole 1% dermal cream in the treatment of dermatomycoses: a multicentre, double-blind, randomized, comparative clinical trial with bifonazole 1% cream. Dermatology 1995; 190: 295–300PubMedCrossRefGoogle Scholar
  45. 45.
    Hay RJ, Roberts DT, Doherty VR, et al. The topical treatment of onychomycosis using a new combined urea/imidazole preparation. Clin Exp Dermatol 1988; 13: 164–7PubMedCrossRefGoogle Scholar
  46. 46.
    Torres-Rodriguez JM, Madrenys N, Nicolas MC. Non-traumatic topical treatment of onychomycosis with urea associated with bifonazole. Mycoses 1991; 34: 499–504PubMedCrossRefGoogle Scholar
  47. 47.
    Arika T, Hase T, Yokoo M. Anti-Trichophyton mentagrophytes activity and percutaneous permeation of butenafine in guinea pigs. Antimicrob Agents Chemother 1993; 37: 363–5PubMedCrossRefGoogle Scholar
  48. 48.
    Clayton YM, Connor BL. Comparison of clotrimazole cream, Whitefield’s ointment and nystatin ointment for the topical treatment of ringworm infection, pityriasis versicolor, erythrasma and candidiasis. Br J Dermatol 1973; 89: 297–303PubMedCrossRefGoogle Scholar
  49. 49.
    Finzi A, Fioroni A, Pretim PM. A double-blind evaluation of fenticonazole cream 2% and clotrimazole cream 1% in dermatomycoses. Mykosen 1986; 29: 41–4PubMedCrossRefGoogle Scholar
  50. 50.
    Lassus A, Forstrom S, Salo O. A double-blind comparison of sulconazole nitrate 1% cream with clotrimazole 1% cream in the treatment of dermatophytoses. Br J Dermatol 1989; 108: 195–8CrossRefGoogle Scholar
  51. 51.
    Smith EB, Breneman DL, Griffith RF, et al. Double-blind comparison of naftifine cream and clotrimazole betamethasone dipropionate cream in the treatment of tinea pedis. J Am Acad Dermatol 1992; 26: 125–7PubMedCrossRefGoogle Scholar
  52. 52.
    Binet O, Soto-Melo J, Delgadillo J, et al. Flutrimazole 1% dermal cream in the treatment of dermatomycoses: a randomized multicentre, double blind, comparative trial with 1% clotrimazole cream. Mycoses 1995; 37: 455–9CrossRefGoogle Scholar
  53. 53.
    Evans EGV. A comparison of terbinafine (Lamisil®) 1% cream given for one week with clotrimazole (Canesten®) 1% cream given for four weeks, in the treatment of tinea pedis. Br J Dermatol 1994; 130 Suppl. 43: 12–4PubMedCrossRefGoogle Scholar
  54. 54.
    Elewski B, Bergstresser PR, Hanifin J. Long-term outcome of patients with interdigital tinea pedis treated with terbinafine or clotrimazole. J Am Acad Dermatol 1995; 32: 290–2PubMedCrossRefGoogle Scholar
  55. 55.
    Del Palacio A, Cuetara S, Rodriguez Noriega A. Topical treatment of tinea corporis and tinea cruris with eberconazole (WAS 2160) cream 1% and 2%: a phase II dose-finding pilot study. Mycoses 1995; 38: 317–28PubMedCrossRefGoogle Scholar
  56. 56.
    Heel RC, Brogden RN, Speight TM, et al. Econazole: a review of its antifungal activity and therapeutic efficacy. Drugs 1978; 16: 177–201PubMedCrossRefGoogle Scholar
  57. 57.
    Grigoriu D, Grigoriu A. Double-blind comparison of the efficacy, toleration and safety of tioconazole base 1% and econazole nitrate 1% creams in the treatment of patients with fungal infections of the skin or erythrasma. Dermatologica 1983; 166 Suppl. 1: 8–13PubMedCrossRefGoogle Scholar
  58. 58.
    Kokoschka EM, Miebauer G, Mounari M, et al. Treatment of dermatomycoses with topical fenticonazole and econazole. Mykosen 1986; 29: 45–50PubMedCrossRefGoogle Scholar
  59. 59.
    Millikan LE, Galen WK, Gewirtzman GM, et al. Naftifine cream 1% versus econazole cream 1% in a treatment of tinea cruris and tinea corporis. J Am Acad Dermatol 1988; 18: 52–6PubMedCrossRefGoogle Scholar
  60. 60.
    Tullio V, Cuffini AM, Carlone NA. In vitro antifungal activities of new imidazole salts towards dermatophytes. Mycoses 1990; 33: 257–63PubMedGoogle Scholar
  61. 61.
    Albanese G, Di Cintio R, Giorgetti P, et al. Recurrent tinea pedis: a double blind study on the prophylactic use of fenticonazole powder. Mycoses 1992; 35: 157–9PubMedCrossRefGoogle Scholar
  62. 62.
    Cugnani HC, Akpata LE, Gugnani MK, et al. Isoconazole nitrate in the treatment of tropical dermatomycoses. Mycoses 1994; 37: 39–41CrossRefGoogle Scholar
  63. 63.
    Greer DL, Jolly HW. Comparative trial of a two-dosage schedule of ketoconazole 2% cream for the treatment of tinea pedis. J Am Acad Dermatol 1987; 17: 53–6PubMedCrossRefGoogle Scholar
  64. 64.
    Clayton YM, Knight AG. A clinical double-blind trial of topical miconazole against superficial fungal infections and erythrasma. Clin Exp Dermatol 1976; 1: 225–32PubMedCrossRefGoogle Scholar
  65. 65.
    Cotterill JA, Evans LGV. Treatment of tinea corporis with miconazole. Br J Clin Pract 1978; 32: 13–4Google Scholar
  66. 66.
    Clayton YM, Gange RW, MacDonald DM, et al. A clinical double-blind trial of topical haloprogin and miconazole against superficial fungal infection. Clin Exp Dermatol 1979; 4: 65–74PubMedCrossRefGoogle Scholar
  67. 67.
    Clayton YM, Hay RJ, McGibbon DH, et al. Double-blind comparison of the efficacy of tioconazole and miconazole for the treatment of fungal infection of the skin or erythrasma. Clin Exp Dermatol 1982; 7: 543–9PubMedCrossRefGoogle Scholar
  68. 68.
    Tanenbaum L, Anderson C, Rosenberg MJ. Sulconazole nitrate 1.0% cream: a comparison with miconazole in the treatment of tinea pedis and tinea cruris/corporis. Cutis 1982; 30: 105–7PubMedGoogle Scholar
  69. 69.
    Fredriksson T. Treatment of dermatomycoses with topical tioconazole and miconazole. Dermatologica 1983; 166: 14–9PubMedCrossRefGoogle Scholar
  70. 70.
    Nolting S, Rogalia K. Double-blind comparison of miconazole/corticosteroid combination versus miconazole in inflammatory dermatomycoses. Int J Dermatol 1995; 34: 125–8PubMedCrossRefGoogle Scholar
  71. 71.
    Rollman O. Treatment of onychomycosis by partial nail avulsion and topical miconazole. Dermatologica 1982; 165: 54–61PubMedCrossRefGoogle Scholar
  72. 72.
    Ramelet AA, Walker-Nasir E. One daily application of oxiconazole cream is sufficient for treating dermatomycoses. Dermatologica 1987; 175: 293–5PubMedCrossRefGoogle Scholar
  73. 73.
    Melchinger W, Polak A, Müller J. The effects of amorolfine and oxiconazole on the ultrastructure of Trichophyton mentagrophytes: a comparison. Mycoses 1988; 33: 393–404Google Scholar
  74. 74.
    Ellis CN, Gammon WR, Goldfarb MT, et al. A placebo-controlled evaluation of once-daily versus twice-daily oxiconazole nitrate (1%) cream in the treatment of tinea pedis. Curr Ther Res 1989; 46: 269–76Google Scholar
  75. 75.
    Jegasothy BV, Pakes GE. Oxiconazole nitrate: pharmacology, efficacy, and safety of a new imidazole antifungal agent. Clin Ther 1991; 13: 126–41PubMedGoogle Scholar
  76. 76.
    Palacin C, Tarrago C, Sacristan A, et al. Antifungal activity of sertaconazole in the cutaneous retention time test. J Mycol Med 1995; 5: 35–9Google Scholar
  77. 77.
    Tanenbaum L, Taplin D, Lavalle C, et al. Sulconazole nitrate cream 1% for treating tinea cruris and corporis. Cutis 1989; 44: 344–7PubMedGoogle Scholar
  78. 78.
    Van Cutsem J, Van Gerven F, Zaman R, et al. Terconazole: a new broad spectrum antifungal. Chemotherapy 1983; 29: 322–31PubMedCrossRefGoogle Scholar
  79. 79.
    Marriott MS, Baird JRC, Brammer KW, et al. Tioconazole, a new imidazole-antifungal agent for the treatment of dermatomycoses. Dermatologica 1983; 166: 1–7PubMedCrossRefGoogle Scholar
  80. 80.
    Clissold SP, Heel RC. Tioconazole: a review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs 1986; 31: 29–51PubMedCrossRefGoogle Scholar
  81. 81.
    Hay RJ, MacKie RM, Clayton YM. Tioconazole nail solution: an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1987; 10: 111–5CrossRefGoogle Scholar
  82. 82.
    Hay RJ, Clayton YM, Moore MK. A comparison of tioconazole 28% nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis. Clin Exp Dermatol 1987; 12: 175–7PubMedCrossRefGoogle Scholar
  83. 83.
    Polak AM. Kinetics of amorolfine in human nails. Mycoses 1993; 36: 101–3PubMedCrossRefGoogle Scholar
  84. 84.
    Zaug M. Amorolfine nail lacquer: clinical experience in onychomycosis. J Eur Acad Dermatol Venereol 1995; 4 Suppl. 1: 23–30CrossRefGoogle Scholar
  85. 85.
    Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil) a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol 1989; 14: 124–7PubMedCrossRefGoogle Scholar
  86. 86.
    Greer DL, Jolly HW. Treatment of tinea cruris with topical terbinafine. J Am Acad Dermatol 1990; 23: 800–4PubMedCrossRefGoogle Scholar
  87. 87.
    Millikan LE. Efficacy and tolerability of topical terbinafine in the treatment of tinea cruris. J Am Acad Dermatol 1990; 23: 795–9PubMedCrossRefGoogle Scholar
  88. 88.
    Savin RC. Treatment of chronic tinea pedis (athlete’s foot type) with topical terbinafine. J Am Acad Dermatol 1990; 23: 786–9PubMedCrossRefGoogle Scholar
  89. 89.
    Evans EGV, James IGV, Joshipura RC. Two-week treatment of tinea pedis with terbinafine (Lamisil) 1% cream: a placebo controlled study. J Dermatol Treat 1991; 2: 95–7CrossRefGoogle Scholar
  90. 90.
    Berman B, Ellis C, Leyden J, et al. Efficacy of a 1 week, twice-daily regimen of terbinafine 1% cream in the treatment of interdigital tinea pedis. J Am Acad Dermatol 1992; 26: 956–60PubMedCrossRefGoogle Scholar
  91. 91.
    Hill ST, Smith SG, Finlay AY. An investigation of the pharmacokinetics of topical terbinafine (Lamisil®) 1 % cream. Br J Dermatol 1992; 127: 396–400PubMedCrossRefGoogle Scholar
  92. 92.
    Jue SG, Dawson GW, Brogden RN. Ciclopirox olamine 1% cream: a preliminary review of its antimicrobial activity and therapeutic use. Drugs 1985; 29: 330–41PubMedCrossRefGoogle Scholar
  93. 93.
    Kligman AM, Bogaert H, Cordero C, et al. Evaluation of ciclopirox olamine cream for the treatment of tinea pedis: multicenter, double-blind comparative studies. Clin Ther 1985; 7: 409–17Google Scholar
  94. 94.
    Bogaert H, Cordero C, Ollague W, et al. Multicentre double-blind clinical trials of cyclopirox olamine cream 1% in the treatment of tinea corporis and tinea cruris. J Int Med Res 1986; 14: 210–6PubMedGoogle Scholar
  95. 95.
    Ceschin-Roques C, Hanel H, Pruja-Bougaret S. Ciclopiroxolamine nail lacquer 8%: in vitro penetration through nails and in vitro effect on pig skin. Skin Pharmacol 1991; 4: 89–94PubMedCrossRefGoogle Scholar
  96. 96.
    Suringa DWR. Treatment of superficial onychomycosis with topically applied glutaraldehyde. Arch Dermatol 1970; 102: 163–7PubMedCrossRefGoogle Scholar
  97. 97.
    Aly R, Bayles C, Oakes RA. Topical griseofulvin in the treatment of dermatophytoses. Clin Exp Dermatol 1994; 19: 43–6PubMedCrossRefGoogle Scholar
  98. 98.
    Mares D, Fasculo MP, Bruni A. Ultraviolet-mediated antimycotic activity of α-terthienyl on Microsporum cookei. J Med Vet Mycol 1990; 28: 469–77PubMedCrossRefGoogle Scholar
  99. 99.
    Mares D, Romangoli C, Rossi R, et al. Antifungal activity of some 2,2′: 5′,2″-tertiophene derivatives. Mycoses 1994; 37: 377–83PubMedGoogle Scholar
  100. 100.
    Smith EB, Dickson JE, Knox JM. Tolnaftate powder in prophylaxis of tinea pedis. South Med J 1979; 67: 776–8CrossRefGoogle Scholar
  101. 101.
    Ishii M, Hamada T, Asai Y. Treatment of onychomycosis by ODT therapy with 20% urea ointment and 2% tolnaftate ointment. Dermatologica 1983; 167: 273–9PubMedCrossRefGoogle Scholar
  102. 102.
    Kishore N, Mishra AK, Chansouria JPN. Fungitoxicity of essential oils against dermatophytes. Mycoses 1993; 36: 211–5PubMedCrossRefGoogle Scholar
  103. 103.
    Pönnighaus JM, Gooskens V, Clayton Y, et al. Treatment of superficial mycoses in the tropics: results of a double-blind trial in Karonga District, Malawi. Mycoses 1994; 37 Suppl. 1: 101–4PubMedGoogle Scholar
  104. 104.
    Garg AP, Müller J. Inhibition of growth of dermatophytes by Indian hair oils. Mycoses 1992; 35: 363–9PubMedCrossRefGoogle Scholar
  105. 105.
    Stiller MJ. Systemic drugs in the treatment of dermatophytoses. Int J Dermatol 1993; 32: 16–21PubMedCrossRefGoogle Scholar
  106. 106.
    Meinhoff W. Kinetics and spectrum of activity of oral antifungals: the therapeutic implications. J Am Acad Dermatol 1993; 29: S37–41CrossRefGoogle Scholar
  107. 107.
    Crounse RG. Human pharmacology of griseofulvin: the effect of fat intake on gastrointestinal absorption. J Invest Dermatol 1961; 37: 529–33PubMedCrossRefGoogle Scholar
  108. 108.
    Shah VP, Epstein WL, Riegelman S. Role of sweat in accumulation of orally administered griseofulvin in skin. J Clin Invest 1974; 53: 1673–8PubMedCrossRefGoogle Scholar
  109. 109.
    Epstein WL, Shah VP, Riegelman S. Griseofulvin levels in stratum corneum: study after oral administration in man. Arch Dermatol 1972; 106: 344–8PubMedCrossRefGoogle Scholar
  110. 110.
    Daneshment TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988; 14: 13–34CrossRefGoogle Scholar
  111. 111.
    Hay RJ. Pharmacodynamic and pharmacokinetic evaluation of fluconazole in skin and nails. Int J Dermatol 1992; 31 Suppl. 2: 6–7Google Scholar
  112. 112.
    Faergemann J, Laufen H. Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum), and eccrine sweat. Clin Exp Dermatol 1993; 18: 102–6PubMedCrossRefGoogle Scholar
  113. 113.
    Wiedfeuer A, Faergemann J, Laufen H, et al. Bioavailability of fluconazole in the skin after oral medication. Mycoses 1994; 37: 127–30CrossRefGoogle Scholar
  114. 114.
    Cauwenbergh G, De Doncker P, Stoops K, et al. Itraconazole in the treatment of human mycoses: review of three years of clinical experience. Rev Infect Dis 1987; 9: S146–52PubMedCrossRefGoogle Scholar
  115. 115.
    Mathieu L, De Doncker P, Cauwenbergh G, et al. Itraconazole penetrates the nail via the nail matrix and the nail bed: an investigation in onychomycosis. Clin Exp Dermatol 1991; 16: 374–6CrossRefGoogle Scholar
  116. 116.
    Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally administered itraconazole in the human skin. J Am Acad Dermatol 1988; 18: 263–8PubMedCrossRefGoogle Scholar
  117. 117.
    De Doncker P, Van Lint J, Dockx P, et al. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis. Cutis 1995; 56: 180–3PubMedGoogle Scholar
  118. 118.
    De Doncker P, Decroix J, Piérard GE, et al. Antifungal pulse therapy in onychomycosis: a pharmacokinetic/pharmacodynamic investigation of monthly cycles of 1 week pulse with itraconazole. Arch Dermatol 1996; 132: 34–41PubMedCrossRefGoogle Scholar
  119. 119.
    Van den Bossche H, Marichal P, Willemsens G, et al. Saperconazole: a selective inhibitor of the cytochrome P-450—dependent ergosterol synthesis in Candida albicans, Aspergillus fumigatus and Trichophyton mentagrophytes. Mycoses 1990; 33: 335–52Google Scholar
  120. 120.
    Zienicke H, Korting HC. Clinical efficacy and tolerability of saperconazole for tinea of glabrous skin: a report on four cases. Mycoses 1993; 36: 131–4PubMedCrossRefGoogle Scholar
  121. 121.
    Dykes PJ, Thomas R, Finlay AY. Determination of terbinafine in nail samples during systemic treatment for onychomycosis. Br J Dermatol 1990; 123: 481–6PubMedCrossRefGoogle Scholar
  122. 122.
    Lever LR, Dykes PJ, Thomas R, et al. How orally-administered terbinafine reaches the stratum corneum. J Dermatol Treat 1990; 1 Suppl. 2: 23–5CrossRefGoogle Scholar
  123. 123.
    Finlay AY. Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992; 126 Suppl. 39: 28–32PubMedCrossRefGoogle Scholar
  124. 124.
    Faergemann J, Zehender H, Denouël J, et al. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250mg terbinafine orally once per day for four weeks. Acta Dermatol Venereol 1993; 73: 305–9Google Scholar
  125. 125.
    Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993; 29: S50–4PubMedCrossRefGoogle Scholar
  126. 126.
    Ottervanger JP, Stricker BHC. Loss of taste and terbinafine. Lancet 1992; 340: 728PubMedCrossRefGoogle Scholar
  127. 127.
    Villars VV, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol 1992; 126 Suppl. 39: 61–9PubMedCrossRefGoogle Scholar
  128. 128.
    Bickers DR. Antifungal therapy: potential interactions with other classes of drugs. J Am Acad Dermatol 1994; 31: S87–90PubMedCrossRefGoogle Scholar
  129. 129.
    Ginsburg CM, Gan VN, Petruska M. Randomized controlled trial of intralesional corticosteroid and griseofulvin vs. griseofulvin alone for treatment of kerion. Pediatr Infect Dis 1987; 6: 1084–7Google Scholar
  130. 130.
    Arikian SR, Einarson TR, Kobelt-Ngyen G. A multinational analysis of oral therapies for onychomycosis. Br J Dermatol 1994; 130 Suppl. 43: 35–44PubMedCrossRefGoogle Scholar
  131. 131.
    Davis R, Balfour JA. Terbinafine: a pharmacoeconomic evaluation of its use in superficial fungal infections. Pharmacoeconomics 1995; 8: 253–69PubMedCrossRefGoogle Scholar
  132. 132.
    Sobh M, El-Agroudy A, Moustafa F, et al. Coadministration of ketoconazole to cyclosporin-treated kidney transplant recipients: a prospective randomized study. Am J Nephrol 1995; 15: 493–9PubMedCrossRefGoogle Scholar
  133. 133.
    Bourlond A, Lachapelle JM, Aussems J, et al. Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris. Int J Dermatol 1989; 28: 410–2PubMedCrossRefGoogle Scholar
  134. 134.
    Lambert DR, Siegle RJ, Camisa C. Griseofulvin and ketoconazole in the treatment of dermatophyte infections. Int J Dermatol 1989; 28: 300–4PubMedCrossRefGoogle Scholar
  135. 135.
    Del Palacio Hernanz A, Lopez Gomez S, Gonzalez Lastra F, et al. A comparative double blind study of terbinafine (Lamisil®) and griseofulvin in tinea corporis and tinea cruris. Clin Exp Dermatol 1990; 15: 210–6CrossRefGoogle Scholar
  136. 136.
    Hay RJ, Clayton YM, Moore MK, et al. Itraconazole in the management of chronic dermatophytosis. J Am Acad Dermatol 1990; 23: 561–4PubMedCrossRefGoogle Scholar
  137. 137.
    Roseeuw D, Willemsen M, t’Kint R, et al. Itraconazole in the treatment of superficial mycoses — a double-blind study vs. placebo. Clin Exp Dermatol 1990; 15: 101–4PubMedCrossRefGoogle Scholar
  138. 138.
    Saul A, Bonifaz A. Itraconazole in common dermatophyte infections of the skin: fixed treatment schedules. J Am Acad Dermatol 1990; 23: 554–8PubMedCrossRefGoogle Scholar
  139. 139.
    Katsambas A, Antoniou CH, Frangouli E, et al. Itraconazole in the treatment of tinea corporis and tinea cruris. Clin Exp Dermatol 1993; 18: 322–5PubMedCrossRefGoogle Scholar
  140. 140.
    Budimulja U, Kuswadji K, Bramono S, et al. A double-blind, randomized, stratified controlled study of the treatment of tinea imbricata with oral terbinafine or itraconazole. Br J Dermatol 1994; 130 Suppl. 43: 29–31PubMedCrossRefGoogle Scholar
  141. 141.
    Degreef H, Mariën K, De Veytler H, et al. Itraconazole in the treatment of dermatophytoses: a comparison of 2 daily dosages. Rev Infect Dis 1987; 1: S104–8CrossRefGoogle Scholar
  142. 142.
    Parent D, Decroix J, Heenen M. Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and/or tinea cruris. Dermatology 1994; 189: 378–81PubMedCrossRefGoogle Scholar
  143. 143.
    Kagawa S. Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis. Clin Exp Dermatol 1989; 14: 114–5PubMedCrossRefGoogle Scholar
  144. 144.
    Jones TC. Overview of the use of terbinafine (Lamisil®) in children. Br J Dermatol 1995; 132: 683–9PubMedCrossRefGoogle Scholar
  145. 145.
    Rippon JW. The changing epidemiology and emerging patterns of dermatophyte species. Curr Top Med Mycol 1985; 1: 209–34Google Scholar
  146. 146.
    Leyden JL. Tinea pedis pathophysiology and treatment. J Am Acad Dermatol 1994; 31: S31–3PubMedCrossRefGoogle Scholar
  147. 147.
    Van Hecke E, Van Cutsem J. Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea pedis and tinea manuum. Mycoses 1988; 31: 641–9PubMedCrossRefGoogle Scholar
  148. 148.
    Savin RC, Zaias N. Treatment of chronic moccasin-type tinea pedis with terbinafine: a double-blind placebo-controlled trial. J Am Acad Dermatol 1990; 23: 804–7PubMedCrossRefGoogle Scholar
  149. 149.
    Hay RJ, Logan RA, Moore MK, et al. A comparative study of terbinafine versus griseofulvin in ‘dry-type’ dermatophyte infections. J Am Acad Dermatol 1991; 24: 243–6PubMedCrossRefGoogle Scholar
  150. 150.
    White JE, Perkins PJ, Evans EGV. Successful 2-week treatment with terbinafine (Lamisil) for moccasin tinea pedis and tinea manuum. Br J Dermatol 1991; 125: 260–2PubMedCrossRefGoogle Scholar
  151. 151.
    De Keyser P, De Backer M, Massart DL, et al. Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind multicentre study. Br J Dermatol 1994; 130 Suppl. 43: 22–5PubMedCrossRefGoogle Scholar
  152. 152.
    Decroix J. Tinea pedis (moccasin-type) treated with itraconazole. Int J Dermatol 1995; 34: 122–4PubMedCrossRefGoogle Scholar
  153. 153.
    Hay RJ, McGregor JM, Wuite J, et al. A comparison of 2 weeks of terbinafine 250 mg/day with 4 weeks of itraconazole 100 mg/day in plantar-type tinea pedis. Br J Dermatol 1995; 132: 604–8PubMedCrossRefGoogle Scholar
  154. 154.
    Legendre R, Esola-Macre J. Itraconazole in the treatment of tinea capitis. J Am Acad Dermatol 1990; 23: 559–60PubMedCrossRefGoogle Scholar
  155. 155.
    Elewski BE. Tinea capitis: itraconazole in Trichophyton tonsurans infections. J Am Acad Dermatol 1994; 31: 65–7PubMedCrossRefGoogle Scholar
  156. 156.
    Lopez-Gomez S, Del Palacio A, Van Cutsem J, et al. Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children. Int J Dermatol 1994; 33: 743–7PubMedCrossRefGoogle Scholar
  157. 157.
    Haroon TS, Hussain I, Mahmoud A, et al. An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis. Br J Dermatol 1992; 126 Suppl. 39: 47–50PubMedCrossRefGoogle Scholar
  158. 158.
    Suarez SM, Silvers DN, Scher RK, et al. Histologic evaluation of nail clippings for diagnosing onychomycosis. Arch Dermatol 1991; 127: 1517–9PubMedCrossRefGoogle Scholar
  159. 159.
    Midgley G, Moore MK, Cook JC, et al. Mycology of nail disorders. J Am Acad Dermatol 1994; 31: S68–73PubMedCrossRefGoogle Scholar
  160. 160.
    Piérard GE, Arrese JE, Pierre S, et al. Diagnostic microscopique des onychomycoses. Ann Dermatol Venereol 1994; 121: 25–9PubMedGoogle Scholar
  161. 161.
    Arrese JE, Piérard-Franchimont C, Greimers R, et al. Fungi in onychomycosis: a study by immunohistochemistry and dual flow cytometry. J Eur Acad Dermatol Venereol 1995; 4: 123–30CrossRefGoogle Scholar
  162. 162.
    Piérard GE, Arrese JE, De Doncker P, et al. Present and potential diagnostic techniques in onychomycosis. J Am Acad Dermatol 1996; 34: 273–7PubMedCrossRefGoogle Scholar
  163. 163.
    Piérard GE, Arrese Estrada J, Piérard-Franchimont C. Treatment of onychomycosis: traditional approaches. J Am Acad Dermatol 1993; 29: S41–5PubMedCrossRefGoogle Scholar
  164. 164.
    Brem J. Effective topical method of therapy for onychomycosis. Cutis 1981; 27: 69–76PubMedGoogle Scholar
  165. 165.
    Faergemann J, Swanbeck G. Treatment of onychomycosis with a propylene glycol urea-lactic acid solution. Mycoses 1989; 32: 536–40PubMedCrossRefGoogle Scholar
  166. 166.
    Cohen PR, Scher RK. Topical and surgical treatment of onychomycosis. J Am Acad Dermatol 1994; 31: S74–7PubMedCrossRefGoogle Scholar
  167. 167.
    Faergeman J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32: 750–3CrossRefGoogle Scholar
  168. 168.
    Haneke E, Tausch I, Bräutigam M, et al. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995; 32: 72–7PubMedCrossRefGoogle Scholar
  169. 169.
    Roseeuw D, De Doncker P. New approaches to the treatment of onychomycosis. J Am Acad Dermatol 1993; 29: 545–50CrossRefGoogle Scholar
  170. 170.
    Roberts DT. Oral therapeutic agents in fungal nail disease. J Am Acad Dermatol 1994; 31: S78–81PubMedCrossRefGoogle Scholar
  171. 171.
    Coldiron B. Recalcitrant onychomycosis of the toenails successfully treated with fluconazole. Arch Dermatol 1992; 128: 909–10PubMedCrossRefGoogle Scholar
  172. 172.
    Kuokkanen K, Alvara S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat 1992; 3: 115–7CrossRefGoogle Scholar
  173. 173.
    Meléndez M, Siles L, Montero-Gei F. Fluconazole treatment of onychomycosis: traditional approaches. J Am Acad Dermatol 1993; 29: 541–5Google Scholar
  174. 174.
    Nahass GT, Sisto M. Onychomycosis: successful treatment with once weekly fluconazole. Dermatology 1993; 186: 59–61PubMedCrossRefGoogle Scholar
  175. 175.
    Hay RJ, Clayton YM, Moore MK, et al. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol 1988; 119: 359–66PubMedCrossRefGoogle Scholar
  176. 176.
    Walsoe I, Stangerup M, Svejgaard E. Itraconazole in onychomycosis: open and double-blind studies. Acta Dermatol Venereol 1990; 70: 137–40Google Scholar
  177. 177.
    Piepponen T, Blomqvist K, Brandt H, et al. Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. J Antimicrob Chem 1992; 29: 195–205CrossRefGoogle Scholar
  178. 178.
    Willemsen M, De Doncker P, Willems J, et al. Post-treatment itraconazole levels in the nail. J Am Acad Dermatol 1992; 26: 731–5PubMedCrossRefGoogle Scholar
  179. 179.
    André J, De Doncker P, Laporte M, et al. Onychomycosis caused by Microsporum canis: treatment with itraconazole. J Am Acad Dermatol 1995; 32: 1052–3PubMedCrossRefGoogle Scholar
  180. 180.
    Zaias N, Serrano L. The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine. Clin Exp Dermatol 1989; 14: 120–3PubMedCrossRefGoogle Scholar
  181. 181.
    Goodfield MJD, Andrew L, Evans EGV. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ 1992; 304: 1151–4PubMedCrossRefGoogle Scholar
  182. 182.
    Van der Schroeff JG, Cirkel PKS, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992; 126 Suppl. 39: 36–9PubMedCrossRefGoogle Scholar
  183. 183.
    Albanese G, Di Cintio R, Martini C, et al. Short therapy for tinea unguium with terbinafine: four different courses of treatment. Mycoses 1995; 38: 211–4PubMedCrossRefGoogle Scholar
  184. 184.
    Matsumoto T, Tanuma H, Kaneko S, et al. Clinical and pharmacokinetic investigations of oral terbinafine in patients with tinea unguium. Mycoses 1995; 38: 135–44PubMedCrossRefGoogle Scholar
  185. 185.
    Tosti A, Piraccini BM, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996; 34: 595–600PubMedCrossRefGoogle Scholar
  186. 186.
    De Doncker P, Piérard GE. Acquired nail beading in patients receiving itraconazole: an indicator of faster nail growth? A study using optical profilometry. Clin Exp Dermatol 1994; 19: 404–6PubMedCrossRefGoogle Scholar
  187. 187.
    Weitzman I, Summerbel R. The dermatophytes. Clin Microbiol Rev 1995; 8: 240–59PubMedGoogle Scholar
  188. 188.
    Piérard-Franchimont C, De Doncker P, Van de Velde V, et al. Paradoxical response to itraconazole treatment in a patient with onychomycosis caused by Microsporum gypseum. Ann Soc Belge Med Trop 1995; 75: 211–7Google Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Géerald E. Piérard
    • 1
  • Jorge E. Arrese
    • 1
  • Claudine Piérard-Franchimont
    • 1
  1. 1.Department of DermatopathologyUniversity of LiègeLiègeBelgium

Personalised recommendations